Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track IMMX with free AI briefings, catalyst countdowns, and dilution alerts.

IMMX · Immix Biopharma, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$232.1M Cash on Hand

64.6mo Cash Runway

Follow IMMX by email Get an email when IMMX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IMMX, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Dec 2026 · Phase 1/2 · Active Trial · Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
Registry primary completion date, not a results date
Dec 2028 · Phase 3 · Upcoming Trial · A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Da
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Dara-CyBorD	Light Chain (AL) Amyloidosis	Phase 3 · NCT07709715	Not yet recruiting
Evarucabgene Autoleucel (NXC-201)	Light Chain (AL) Amyloidosis	Phase 3 · NCT07709715	Not yet recruiting
Curcumin/Doxorubicin-encapsulating Nanop	Solid Tumor, Adult	Phase 1/2 · NCT03382340	Unknown

Also used in these trials (approved or third-party drugs, not IMMX's own candidates): Tislelizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IMMX holds $232.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $10.8M/quarter from operations, an estimated runway of 64.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 20 · Moderate

Cash runway 65 months
Share count +148% in a year +20

Recent financing filings on SEC EDGAR:

Sep 8, 2025 · Private placement (8-K Item 3.02) · 8-K
May 20, 2024 · Private placement (8-K Item 3.02) · 8-K

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMMX files for a raise →

Get the full IMMX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMMX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z